 |
| Image Prompted by Human Ideas & Generated by AI |
I recently read the book “Bad Blood” by John Carreyrou (See Reference below) and want to share my take on this absolute marvel of investigative reporting. For those of you who may not know the story of Theranos, the Biotech company, I have tried to make his work a little more approachable and concise. I do recommend reading this fantastic book which I thought was gripping!
“Every great innovation begins with an idea. But in medicine, unlike many other industries, an inspiring idea is only the beginning. It must ultimately answer to scientific truth.”
There are some books that entertain us, some that educate us, and a rare few that leave us asking a much deeper question: How could this have happened? Bad Blood: Secrets and Lies in a Silicon Valley Startup belongs firmly in that last category.
The story of Theranos is not merely the story of a failed startup. It is a cautionary tale about what happens when ambition, money, media attention, and the desire for a revolutionary breakthrough come together without the discipline of scientific validation.
What makes Bad Blood such a fascinating and unsettling read is that the idea behind Theranos sounded like exactly the kind of medical innovation the world needed. Imagine a future where a patient could walk into a pharmacy or clinic, provide only a few drops of blood, and receive dozens of important health results quickly and inexpensively. For patients, doctors, and healthcare systems struggling with cost and accessibility, this vision was incredibly appealing.
The problem was not the dream. Healthcare has always advanced because people dared to imagine what seemed impossible. The problem was that the promise moved far ahead of the evidence.
As someone who has spent a career in healthcare, I have always believed that innovation is essential. Medicine cannot progress without curiosity, experimentation, and people willing to challenge the status quo. But healthcare has one responsibility that separates it from many other industries: the consequences of failure involve human lives.
A flawed smartphone app may inconvenience a user. A flawed medical device or inaccurate diagnostic test can lead to a wrong diagnosis, unnecessary treatment, or a missed opportunity to save a life.
This is what makes the Theranos story so disturbing. The company did not simply develop a technology that failed to meet expectations. According to Carreyrou’s investigation, it created an environment where questioning the technology became difficult, where secrecy replaced transparency, and where the image of success became almost as important as the science itself.
The most powerful lesson from Bad Blood is that appearances can be incredibly persuasive. Theranos surrounded itself with influential investors, respected board members, and a compelling narrative about changing the future of medicine. Many intelligent and accomplished people wanted to believe the story because the story represented something inspiring: a young entrepreneur disrupting an outdated system and bringing healthcare closer to ordinary people.
But science does not advance through inspiration alone. It advances through evidence, peer review, replication, and the willingness to admit when something does not work.
That lesson extends far beyond Theranos. We may now live in an era where technology companies can become billion-dollar enterprises based largely on vision and expectation. Artificial intelligence, biotechnology, and other emerging fields hold enormous potential, but they also create opportunities for exaggeration. Society often celebrates the visionary before asking the harder questions: Does it actually work? Is it safe? Has it been independently verified?
These questions are not meant to discourage innovation. They are meant to protect it.
One of the most important themes in Bad Blood is the role of accountability. Healthy organizations need people who can challenge leadership, raise concerns, and question assumptions. When employees, regulators, journalists, or experts are discouraged from speaking openly, the consequences can be profound.
The courage of whistleblowers and investigative journalists reminds us that truth often requires persistence. In Theranos’s case, it was not one dramatic moment that revealed the problems. It was the gradual accumulation of questions from people who refused to accept that a powerful story was more important than scientific reality.
For me, the greatest takeaway from Bad Blood is not simply that Theranos failed. Many companies fail. Failure itself is part of innovation. The deeper issue is what happens when society becomes so captivated by a promise that it stops demanding proof.
We should celebrate dreamers. We should encourage entrepreneurs. We should support scientific breakthroughs. But we must never confuse confidence with competence, popularity with credibility, or a compelling story with the truth.
The history of medicine teaches us that genuine breakthroughs are rarely built on secrecy and shortcuts. They are built on patience, skepticism, testing, and evidence.
Bad Blood is ultimately a reminder of a principle that should guide every medical and technological revolution:
Extraordinary claims may inspire us — but only extraordinary evidence should convince us.
For anyone interested in healthcare, technology, entrepreneurship, or simply understanding how a modern illusion became one of the most significant business scandals of the twenty-first century, Bad Blood is a book worth reading. It is not just the story of Theranos. It is a lesson about the responsibility that comes with the power to promise the future.
Ref:
